Project Grant K99HL181185
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$131K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02142, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $159,624 to Vanderbilt University Medical Center to conduct research on hypoxia-inducible factor (HIF)-driven modulation of alveolar regeneration. The research aims to investigate how HIF activation impacts cellular fate and epigenetic programs during alveolar repair, as well as the metabolic processes underlying HIF suppression...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at Northwestern University to investigate the role of mitochondrial metabolism in alveolar epithelial cell differentiation and the development of lung fibrosis. The $616,000 award, effective September 1, 2024 through August 31, 2029, will support experiments using genetic mouse models to determine how mitochondrial...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $844,386 to support research on the genetic landscape of childhood interstitial and diffuse lung diseases (CHILD). The key objectives are to: 1) Define molecular profiles of 300 CHILD lung biopsy samples to identify patient clusters with similar underlying causes, 2) Analyze whole exome sequence data from 400 children with...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
This $940,320 Cooperative Agreement awarded by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports a 5-year research project led by Vanderbilt University Medical Center to investigate the molecular mechanisms underlying chronic parenchymal lung diseases like pulmonary fibrosis and bronchopulmonary dysplasia. The project aims to develop a spatially-resolved molecular atlas of chronic lung diseases,...
The federal Project Grant award R01HL177087 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $605,678 award supports research to explore a novel mechanism regulating genome-wide mRNA expression in hypoxic lung disease. Specifically, the research aims to investigate how reactive oxygen species generated during hypoxia induce oxidative modifications in DNA regulatory sequences, which recruit enzymes that...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,061,189 to the Regents of the University of Michigan to conduct research on immune crosstalk in lung injury and fibrosis. The key objectives are to study epithelial cell regulation of fibrosis and its interaction with myeloid cells, uncover mechanisms for impaired innate immunity against gram-positive infections in fibrosis, test delivery of targeted therapeutics...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA 93.837 - Cardiovascular Diseases Research, provides $1,302,038 to the Regents of the University of Michigan to conduct research on targeting dysfunctional epithelial repair in pulmonary fibrosis. The research aims to elucidate the mediators and pathways that contribute to dysfunctional epithelial phenotypes in persistent lung fibrosis, determine the impact of hypoxia-inducible factor (HIF) signaling...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $740,317 to The Washington University in St. Louis to conduct research on the regulation of alveologenesis, the final phase of lung development, by FGF signaling pathways. The research aims to identify the cellular mechanisms by which FGF signaling regulates cell proliferation, differentiation, and death during the first and second stages...